

Suspect Adverse Drug Reaction Reporting Form
 For further assistance please contact 1800 780 169
Please email completed form to: aumedinfo@octapharma.com

Local Case No (internal use only):

REPORTER INFORMATION

Date:	Name of Reporter:
Reporter's Position: <input type="checkbox"/> Physician <input type="checkbox"/> Nurse <input type="checkbox"/> Pharmacist <input type="checkbox"/> Other (specify):	
Institution:	
Telephone No. (including area code):	Email:

PATIENT INFORMATION & HISTORY

Patient Initials:	Date of Birth (dd/mm/yy):	Gender: <input type="checkbox"/> M <input type="checkbox"/> F; <input type="checkbox"/> Pregnant:	wks
Weight (kg):	Age (years):	Blood Group/Rh factor:	
Relevant Family History of Disease: <input type="checkbox"/> Yes (specify below) <input type="checkbox"/> None <input type="checkbox"/> Unknown			
Concomitant Illnesses and Disease: <input type="checkbox"/> Yes (specify below) <input type="checkbox"/> None <input type="checkbox"/> Unknown			
Was the patient taking any concomitant medications? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
If yes, please specify (include product, dose, route of administration, indication for use, frequency):			

ADVERSE DRUG REACTION (ADR) INFORMATION

Description of ADR:	
Date of onset of ADR (dd/mm/yy):	Duration of ADR (min/hrs/days):
Time of onset of ADR after administration of suspected drug (e.g. 30 minutes):	
Diagnosis of ADR (including methods used and laboratory results, units, normal ranges):	
Action taken with suspect product? Choose an item.	If the infusion was stopped, did ADR abate? Choose an item.
Did reaction(s) reappear after reintroduction? Choose an item.	
If yes, please specify date and time of reintroduction:	
Was treatment of ADR required? Choose an item.	
If yes, please specify product, dose, route of administration, therapy dates:	
ADR outcome: Choose an item.	
Seriousness Assessment: <input type="checkbox"/> Non-serious <input type="checkbox"/> Serious (please classify according to at least one of the criteria below)	
<input type="checkbox"/> Life threatening	<input type="checkbox"/> Resulting in persistent or significant disability/incapacity
<input type="checkbox"/> Resulting in congenital anomaly or birth defect	<input type="checkbox"/> Suspected transmission of an infectious agent
<input type="checkbox"/> Patient hospitalised; date from _____ to _____	
<input type="checkbox"/> Hospitalisation prolonged; date from _____ to _____	
<input type="checkbox"/> Fatal; date of death: _____	Autopsy performed: Choose an item. Cause of death: _____
<input type="checkbox"/> Other, please specify:	

Suspect Adverse Drug Reaction Reporting Form
 For further assistance please contact 1800 780 169
Please email completed form to: aumedinfo@octapharma.com

SUSPECT PRODUCT INFORMATION

Product (including concentration):	Route of Administration:
Batch No.(s):	
Daily Dose(s):	Infusion Rate:
Therapy Dates (from/to):	Therapy Duration:
Indication for Use:	
Has the patient previously received treatment with the suspect product?	Choose an item.
Has the patient previously experienced ADRs with the suspect product?	Choose an item.
Has the patient previously experienced ADRs with similar products?	Choose an item.
Causality of suspect product to the ADR: Choose an item.	
Other Comments:	

Octapharma is collecting this information to enable us to process and manage the adverse event which you have reported and to communicate with you and others about this matter. As you are providing us information about a patient, we ask that you please inform them that: you have provided this information to Octapharma; we will only use or disclose it for the purposes outlined above; we may disclose this information to service providers which assist in providing our products and services, including distribution and IT services, and to Octapharma's subsidiary located in Austria; and that the Octapharma Privacy Policy (www.octapharma.com.au) contains more details including how to access or correct personal information, and how to make a complaint in relation to Octapharma's handling of such information.